Am J Transplant, Volume 22, Suppl 3 Archives - Page 11 of 190 - ATC Abstracts

2022 American Transplant Congress
Broad Panel Genetic Testing for Chronic Kidney Disease in the Transplant Center
A. Bhalla¹, D. Raible², V. Balaraman¹, M. Talwar¹
¹James D. Eason Transplant Institute, Methodist University Hospital, Memphis, TN, ²Natera, Inc., Austin, TX
*Purpose: Genetic testing is an emerging tool for ‌the evaluation of patients with end-stage renal disease (ESRD). In kidney transplantation (KT), testing can identify disease…
2022 American Transplant Congress
Absolute Quantification of Donor-Derived Cell-Free DNA Does Not Provide Additional Discriminating Power Over Donor-derived Cell-Free DNA Fraction for Detection of Allograft Rejection
R. Gohh¹, S. Jordan², R. N. Woodward³, K. M. Clark-Langone³, J. Morlan³, B. Silva³, M. Weir⁴
¹Alpert School of Medicine Brown University, Providence, RI, ²Cedars Sinai Medical Ctr, Los Angeles, CA, ³CareDx, Redwood City, CA, ⁴University of Maryland School of Medicine, Baltimore, MD
*Purpose: High level of background cell-free DNA (cfDNA) has been hypothesized as a concern for false negative results in molecular diagnostics for allograft rejection that…
2022 American Transplant Congress
The Perspective of General Nephrologists Toward Transitions of Care and Management of Patients with Failing Kidney Allografts
T. Alhamad¹, H. Murad¹, D. Dadhania², M. Pavlakis³, S. Parajuli⁴, B. P. Concepcion⁵, N. Singh⁶, N. Murakami⁷, M. Casey⁸, M. Ji¹, M. Lubetzky⁹, E. Tantisattamo¹⁰, O. Alomar¹, A. Faravardeh¹¹, C. Blosser¹², A. Basu¹³, M. Molnar¹⁴, G. Gupta¹⁵, J. T. Adler¹⁶, D. Adey¹⁷, K. J. Woodside¹⁸, R. Parsons¹³, K. Lentine¹⁹
¹Wash U in St. Louis, Saint Louis, MO, ²Weill Cornell Med, New York, NY, ³Beth Israel, Boston, MA, ⁴U of Wisconsin, Madison, WI, ⁵Vanderbilt U, Nashville, TN, ⁶Northwell Health, Great neck, NY, ⁷Brigham and Women, Boston, MA, ⁸MUSC, Charleston, SC, ⁹Weill Cornell Medicine, New York, NY, ¹⁰UCI, Orange, CA, ¹¹SHARP, San Diego, CA, ¹²U of Washington, Seattle, WA, ¹³Emory U, Atlanta, GA, ¹⁴U of Utah, Salt Lake City, UT, ¹⁵VCU, Richmond, VA, ¹⁶Surgery, Brigham and Women, Boston, MA, ¹⁷UCSF, San Francisco, CA, ¹⁸U of Michigan, Ann Arbor, MI, ¹⁹Saint Louis U, Saint Louis, MO
*Purpose: Failing kidney allograft with subsequent return to dialysis is associated with high risk of morbidity and mortality. This project aimed to examine general nephrologist…
2022 American Transplant Congress
BK Polyomavirus Infection is Not Associated with a Meaningful Increase in Donor-Derived Cell-Free DNA
J. Fisher¹, K. Vieira¹, R. Burke², R. Gohh¹, R. Rogers¹
¹Warren Alpert Medical School of Brown University, Providence, RI, ²CareDx, Brisbane, CA
*Purpose: Donor-derived cell-free DNA (dd-cfDNA) is a non-invasive measure of early allograft injury that has been clinically validated as a surveillance tool to detect antibody…
2022 American Transplant Congress
Tuberculosis (TB) Treatment without Rifampin in Kidney (K) and Kidney-Pancreas (KP) Transplantation (Tx)
M. V. Radisic¹, N. Pujato¹, P. M. Bravo¹, R. Del Grosso², M. Hunter², S. Beltramino³, L. Cornet¹, R. Livia Franzini⁴, A. C. Dotta⁴, L. Leon⁴, J. Walther⁴, P. Uva⁵, G. Werber³, M. C. Rial⁴
¹Infectious Diseases, ITAC (Instituto de Trasplante y Alta Complejidad), Ciudad Autonoma de Buenos Aires, Argentina, ²Internal Medicine, ITAC (Instituto de Trasplante y Alta Complejidad), Ciudad Autonoma de Buenos Aires, Argentina, ³Critical Care, ITAC (Instituto de Trasplante y Alta Complejidad), Ciudad Autonoma de Buenos Aires, Argentina, ⁴Kidney Transplantation, ITAC (Instituto de Trasplante y Alta Complejidad), Ciudad Autonoma de Buenos Aires, Argentina, ⁵Kidney Pancreas Transplantation, ITAC (Instituto de Trasplante y Alta Complejidad), Ciudad Autonoma de Buenos Aires, Argentina
*Purpose: TB is a diagnostic and therapeutic challenge in K/KP Tx. Pharmacokinetic interaction between rifampin (RFP) and mTOR /calcineurin inhibitors (CNI) led to use of…
2022 American Transplant Congress
Single Dose Alemtuzemab Provides Comparable Rejection Free and Infection Free Survival Compared to Double Dose Alemtuzumab. In Comparison to Alemtuzemab, Basiliximab Has Superior Infection Free Graft Survival. Results from a Steroid Sparing Transplant Group
H. Sharma, A. Odugoudar, B. Devkaran, A. Rao, A. El-Bakry, T. Gunawardhane, D. Ridgway, M. Howse, S. Mehra
Department of Transplant Surgery, Royal Liverpool University Hospital, Liverpool, United Kingdom
*Purpose: The present study investigated the short-term biopsy-proven acute rejection rates and viral infection rates amongst our protocol of single-dose Alemtuzemab (Cohort 1) versus double…
2022 American Transplant Congress
Daratumumab Therapy Achieves Dialysis Independence in Kidney Transplant Recipients with Resistant Proliferative Glomerulonephritis with Monoclonal Immunoglobulin Deposits
P. Yenebere, R. Daloul
The Ohio State University, Columbus, OH
*Purpose: Proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) is a unique cause for monoclonal gammopathy of renal significance with overall poor prognosis. Patients are frequently…
2022 American Transplant Congress
Bystander Suppression: Enhancing the Power of Ex Vivo Expanded Antigen Specific Regulatory Cell Lines
S. Tripathi¹, P. L. Martin-Moreno², G. J. Kavalam³, B. Schreiber³, A. Wagaa-Gasser¹, A. Chandraker⁴
¹Renal, Brigham and Women's Hospital, Boston, MA, ²Nephrology, Clinica Universidad de Navarra, Ripagaina, Spain, ³Brigham and Women's Hospital, Boston, MA, ⁴Medicine, Brigham and Women's Hospital, Boston, MA
*Purpose: The potential of T regulatory cell (Treg) based therapies in transplantation has been demonstrated in various preclinical models. Multiple clinical trials are currently undergoing…
2022 American Transplant Congress
Benefits and Risks of Induction Immunosuppression Therapy in Pediatric Liver Transplantation
T. Bittermann, P. Abt
University of Pennsylvania, Philadelphia, PA
*Purpose: To investigate trends in induction therapy use in pediatric liver transplantation (LT) in the U.S. and evaluate the potential benefits and risks of induction…
2022 American Transplant Congress
Characteristics of OPOs with Increased Education Spending, 2013-2018
J. Roberts¹, J. L. Bragg-Gresham², T. Peters³, F. McCormick⁴
¹University of California-San Francisco, San Francisco, CA, ²University of Michigan, Ann Arbor, MI, ³University of Florida, Jacksonville, FL, ⁴Bank of America (former), Walnut Creek, CA
*Purpose: OPO spending on education would be expected to increase donor registration and increase the number of donors. Using data from multiple sources, we examined…